Kimoto Y, Tanji Y, Tanaka T, Taguchi T
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1884-9.
Allogeneic LAK cells induced from PBL of normal donors were used for adoptive immunotherapy of malignant diseases. The possibility of an antibody against allogeneic LAK cells was suggested. However, no immune reaction was observed and LAK activity was maintained in vitro in the presence of patient's plasma sampled during the course of therapy.
从正常供体的外周血淋巴细胞（PBL）诱导产生的同种异体淋巴因子激活的杀伤细胞（LAK细胞）被用于恶性疾病的过继性免疫治疗。有人提出存在针对同种异体LAK细胞抗体的可能性。然而，未观察到免疫反应，并且在治疗过程中采集的患者血浆存在的情况下，LAK活性在体外得以维持。
